EP2984171A2 - Peptides having immune suppresive domains for transfection - Google Patents
Peptides having immune suppresive domains for transfectionInfo
- Publication number
- EP2984171A2 EP2984171A2 EP14722536.1A EP14722536A EP2984171A2 EP 2984171 A2 EP2984171 A2 EP 2984171A2 EP 14722536 A EP14722536 A EP 14722536A EP 2984171 A2 EP2984171 A2 EP 2984171A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- peptide
- kit
- parts
- virus
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 319
- 238000001890 transfection Methods 0.000 title claims abstract description 63
- 102000004196 processed proteins & peptides Human genes 0.000 title description 32
- 230000006028 immune-suppresssive effect Effects 0.000 claims abstract description 113
- 239000000539 dimer Substances 0.000 claims abstract description 42
- 230000008629 immune suppression Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 129
- 239000000203 mixture Substances 0.000 claims description 112
- 241000700605 Viruses Species 0.000 claims description 85
- 230000004927 fusion Effects 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 42
- 102000037865 fusion proteins Human genes 0.000 claims description 39
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 239000012528 membrane Substances 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 239000002502 liposome Substances 0.000 claims description 29
- 108020004414 DNA Proteins 0.000 claims description 28
- 150000002632 lipids Chemical class 0.000 claims description 28
- 230000002209 hydrophobic effect Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 20
- 125000002091 cationic group Chemical group 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 17
- 230000034217 membrane fusion Effects 0.000 claims description 17
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 12
- 239000012096 transfection reagent Substances 0.000 claims description 12
- 230000037431 insertion Effects 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 7
- 150000008574 D-amino acids Chemical class 0.000 claims description 6
- 238000001415 gene therapy Methods 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 230000010472 type I IFN response Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 102000014914 Carrier Proteins Human genes 0.000 claims description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims description 5
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 4
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 230000030279 gene silencing Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 2
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 2
- 101000937305 Drosophila melanogaster Protein aubergine Proteins 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000010468 interferon response Effects 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 125000003473 lipid group Chemical group 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 description 54
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 47
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 41
- 238000006467 substitution reaction Methods 0.000 description 26
- 230000001506 immunosuppresive effect Effects 0.000 description 25
- 230000004044 response Effects 0.000 description 20
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 19
- -1 His Chemical compound 0.000 description 17
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 17
- 229920006008 lipopolysaccharide Polymers 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 150000004665 fatty acids Chemical class 0.000 description 15
- 150000002327 glycerophospholipids Chemical class 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000003993 interaction Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 239000012097 Lipofectamine 2000 Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 102000053602 DNA Human genes 0.000 description 9
- 230000014567 type I interferon production Effects 0.000 description 9
- 241000713137 Phlebovirus Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 7
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 7
- 241000255129 Phlebotominae Species 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 150000003505 terpenes Chemical class 0.000 description 7
- 241000711950 Filoviridae Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 229930182558 Sterol Natural products 0.000 description 6
- 206010051511 Viral diarrhoea Diseases 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 235000003702 sterols Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100041033 Golgin subfamily B member 1 Human genes 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000531454 Reptilian ferlavirus Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 244000309457 enveloped RNA virus Species 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 150000002313 glycerolipids Chemical class 0.000 description 4
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 108010053687 macrogolgin Proteins 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229930001119 polyketide Natural products 0.000 description 4
- 125000000830 polyketide group Chemical group 0.000 description 4
- 150000003313 saccharo lipids Chemical class 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 208000001490 Dengue Diseases 0.000 description 3
- 206010012310 Dengue fever Diseases 0.000 description 3
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 241000711828 Lyssavirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 3
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 241000710799 Rubella virus Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 241000710886 West Nile virus Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 208000025729 dengue disease Diseases 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000000799 fusogenic effect Effects 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003410 sphingosines Chemical class 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 241000256186 Anopheles <genus> Species 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 241000112287 Bat coronavirus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 241000530623 Bovine viral diarrhea virus 2 Species 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 241001441409 Caraparu virus Species 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 2
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930186185 Polyprenol Natural products 0.000 description 2
- 229920001731 Polyprenol Polymers 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000907520 Rio Bravo virus Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 150000002193 fatty amides Chemical class 0.000 description 2
- 150000002194 fatty esters Chemical class 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000003019 phosphosphingolipids Chemical class 0.000 description 2
- 150000003096 polyprenols Chemical class 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003135 prenol lipids Chemical class 0.000 description 2
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- KYQCXUMVJGMDNG-UHFFFAOYSA-N 3-Desoxy-D-manno-octulosonsaeure Natural products OCC(O)C(O)C(O)C(O)CC(=O)C(O)=O KYQCXUMVJGMDNG-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 241000427202 Adria Species 0.000 description 1
- 241000831748 Aedes flavivirus Species 0.000 description 1
- 241001222053 Akabane virus Species 0.000 description 1
- 241000636855 Alpaca coronavirus CA08-1/2008 Species 0.000 description 1
- 101000700937 Amsacta albistriga Sex-specific storage protein 1 Proteins 0.000 description 1
- 241000007422 Amur virus Species 0.000 description 1
- 241000272522 Anas Species 0.000 description 1
- 241000830224 Anhanga virus Species 0.000 description 1
- 241000436365 Anhembi virus Species 0.000 description 1
- 241000355660 Apeu virus Species 0.000 description 1
- 241000907515 Apoi virus Species 0.000 description 1
- 241001550866 Aravan lyssavirus Species 0.000 description 1
- 241000830898 Arumowot virus Species 0.000 description 1
- 241001351103 Atlantic salmon respirovirus Species 0.000 description 1
- 241000907523 Bagaza virus Species 0.000 description 1
- 241001493167 Bakau virus Species 0.000 description 1
- 241000383457 Batama virus Species 0.000 description 1
- 241000150488 Bayou orthohantavirus Species 0.000 description 1
- 241000436401 BeAr328208 virus Species 0.000 description 1
- 241000685566 Beilong virus Species 0.000 description 1
- 241000856952 Bird droppings coronavirus Species 0.000 description 1
- 241001118702 Border disease virus Species 0.000 description 1
- 241000557764 Border disease virus - X818 Species 0.000 description 1
- 241001235251 Border disease virus 1 Species 0.000 description 1
- 241001235164 Border disease virus 2 Species 0.000 description 1
- 241001238422 Border disease virus 3 Species 0.000 description 1
- 241001118570 Border disease virus isolates Species 0.000 description 1
- 241000713686 Bovine lentivirus group Species 0.000 description 1
- 241000489313 Bovine viral diarrhea virus 3 Species 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- 241000755295 Bruconha virus Species 0.000 description 1
- 241000830941 Bujaru virus Species 0.000 description 1
- 241001493147 Bwamba orthobunyavirus Species 0.000 description 1
- 241000430978 Calabazo virus Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000709807 Catacamas virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000832208 Chagres virus Species 0.000 description 1
- 241000272161 Charadriiformes Species 0.000 description 1
- 241000334972 Chicken enteric coronavirus Species 0.000 description 1
- 241000832209 Chilibre virus Species 0.000 description 1
- 241000196348 Chimeric human parainfluenza virus rPIV3-2 Species 0.000 description 1
- 241000430977 Choclo virus Species 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 241001638933 Cochlicella barbara Species 0.000 description 1
- 241001212104 Corfou virus Species 0.000 description 1
- 241001504212 Coronavirus red knot/p60/2006/GBR Species 0.000 description 1
- 241000907509 Cowbone Ridge virus Species 0.000 description 1
- 241000831747 Culex flavivirus Species 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241001520695 Duvenhage lyssavirus Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000907514 Entebbe bat virus Species 0.000 description 1
- 241000713692 Equine lentivirus group Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 241000713689 Feline lentivirus group Species 0.000 description 1
- 241000521717 Ferret enteric coronavirus 1202 Species 0.000 description 1
- 241000521718 Ferret systemic coronavirus MSU-S Species 0.000 description 1
- 241000521723 Ferret systemic coronavirus WADL Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000710766 Flavivirus sp. Species 0.000 description 1
- 241000714188 Friend murine leukemia virus Species 0.000 description 1
- 241001378033 Frijoles virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000832192 Gabek Forest virus Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000407808 Guangxi coronaviridae Species 0.000 description 1
- 241001085316 Guinea pig parainfluenza virus TS-9 Species 0.000 description 1
- 241000755301 Gumbo Limbo virus Species 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000134307 Hepatitis C virus genotype 1 Species 0.000 description 1
- 241000122128 Hepatitis C virus genotype 2 Species 0.000 description 1
- 241001093325 Hepatitis C virus genotype 3 Species 0.000 description 1
- 241001466980 Hepatitis C virus genotype 4 Species 0.000 description 1
- 241001466982 Hepatitis C virus genotype 5 Species 0.000 description 1
- 241000143279 Hepatitis C virus genotype 6 Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000972245 Hog cholera virus strain Zoelen Species 0.000 description 1
- 241000516895 Human coronavirus NO Species 0.000 description 1
- 244000309469 Human enteric coronavirus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000609530 Ilheus virus Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000059510 Ingwavuma virus Species 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000555269 Ippy mammarenavirus Species 0.000 description 1
- 241001058059 Irkut lyssavirus Species 0.000 description 1
- 241000832191 Itaporanga virus Species 0.000 description 1
- 241001635766 J-virus Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000907342 Jugra virus Species 0.000 description 1
- 241000907512 Jutiapa virus Species 0.000 description 1
- 241000907327 Kadam virus Species 0.000 description 1
- 241001600488 Kairi virus Species 0.000 description 1
- 241001623002 Kamiti River virus Species 0.000 description 1
- 150000000963 Kdo2-lipid A derivatives Chemical class 0.000 description 1
- 241000907328 Kedougou virus Species 0.000 description 1
- 241000178323 Kokobera virus Species 0.000 description 1
- 241000907540 Kokobera virus group Species 0.000 description 1
- 241000178324 Koutango virus Species 0.000 description 1
- 241001466978 Kyasanur forest disease virus Species 0.000 description 1
- MNQZXJOMYWMBOU-GSVOUGTGSA-N L-(-)-glyceraldehyde Chemical compound OC[C@H](O)C=O MNQZXJOMYWMBOU-GSVOUGTGSA-N 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 241001520693 Lagos bat lyssavirus Species 0.000 description 1
- 241000710770 Langat virus Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000436399 Macaua virus Species 0.000 description 1
- 241000755303 Madrid virus Species 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241001135631 Marituba virus Species 0.000 description 1
- 241001492366 Meaban virus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001643857 Menangle virus Species 0.000 description 1
- 241000059506 Mermet virus Species 0.000 description 1
- 241000311126 Mink coronavirus strain WD1133 Species 0.000 description 1
- 241000555271 Mobala mammarenavirus Species 0.000 description 1
- 241000907337 Modoc virus Species 0.000 description 1
- 241000725171 Mokola lyssavirus Species 0.000 description 1
- 241000712897 Mopeia mammarenavirus Species 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000943727 Mosquito flavivirus Species 0.000 description 1
- 241000985150 Mossman virus Species 0.000 description 1
- 241000670735 Muju virus Species 0.000 description 1
- 241000216220 Muleshoe hantavirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001455612 Murayama virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 241000755156 Murutucu virus Species 0.000 description 1
- 241000288894 Myotis Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 241000433860 Naples virus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000755161 Nepuyo virus Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000168432 New York hantavirus Species 0.000 description 1
- 241000143798 Ngoye virus Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 241000253753 Nounane virus Species 0.000 description 1
- 241000907507 Ntaya virus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241001493141 Nyando virus Species 0.000 description 1
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 1
- 241000982791 Oran virus Species 0.000 description 1
- 241001441403 Oriboca virus Species 0.000 description 1
- 241000250439 Oropouche virus Species 0.000 description 1
- 241000755293 Ossa virus Species 0.000 description 1
- 241000713747 Ovine lentivirus Species 0.000 description 1
- 241001219104 Ovine parainfluenza virus 3 Species 0.000 description 1
- 241000713695 Ovine/caprine lentivirus group Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000756202 Pacific salmon paramyxovirus Species 0.000 description 1
- 241000448792 Pacific salmon paramyxovirus Trask River 1983 Species 0.000 description 1
- 241000711502 Paramyxovirinae Species 0.000 description 1
- 241001052830 Parrot coronavirus AV71/99 Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241001230673 Pestivirus isolate 97-360 Species 0.000 description 1
- 241001230320 Pestivirus isolate Hay 87/2210 Species 0.000 description 1
- 241001428801 Pestivirus sp. Species 0.000 description 1
- 241000568311 Pestivirus sp. strain 178003 Species 0.000 description 1
- 241001609484 Pestivirus strain mousedeer Species 0.000 description 1
- 241000572735 Pestivirus type 1 isolates Species 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 241001671206 Phlebotomus flavivirus Alg_F19 Species 0.000 description 1
- 241001671280 Phlebotomus flavivirus Alg_F8 Species 0.000 description 1
- 241000419348 Phlebovirus AH12 Species 0.000 description 1
- 241000242408 Phlebovirus Adria/ALB5/2005 Species 0.000 description 1
- 241000830245 Phlebovirus B105-05 Species 0.000 description 1
- 241000830247 Phlebovirus B151-04 Species 0.000 description 1
- 241000830249 Phlebovirus B43-02 Species 0.000 description 1
- 241000830251 Phlebovirus B68-03 Species 0.000 description 1
- 241000830222 Phlebovirus B79-02 Species 0.000 description 1
- 241000986464 Phlebovirus Chios-A Species 0.000 description 1
- 241000013420 Phlebovirus Cyprus Species 0.000 description 1
- 241000961042 Phlebovirus Hu/Xinyang2/China/2010 Species 0.000 description 1
- 241000830223 Phlebovirus IB13-04 Species 0.000 description 1
- 241000281625 Phlebovirus JS2007-01 Species 0.000 description 1
- 241000206378 Phlebovirus JS24 Species 0.000 description 1
- 241000206376 Phlebovirus JS26 Species 0.000 description 1
- 241000206374 Phlebovirus JS6 Species 0.000 description 1
- 241000739502 Phlebovirus JSD1 Species 0.000 description 1
- 241000871327 Phlebovirus XLL/China/2009 Species 0.000 description 1
- 241000446480 Phlebovirus tick/XCQ-2011 Species 0.000 description 1
- 241001156281 Phocine distemper virus 1 Species 0.000 description 1
- 241001135671 Phocine distemper virus-2 Species 0.000 description 1
- 241000711899 Phocine morbillivirus Species 0.000 description 1
- 241000253407 Pilot whale morbillivirus Species 0.000 description 1
- 241001332277 Porcine parainfluenza virus Species 0.000 description 1
- 241000750429 Porcine paramyxovirus strain Texas Species 0.000 description 1
- 241000520007 Porcine rubulavirus Species 0.000 description 1
- 241000710884 Powassan virus Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000150264 Puumala orthohantavirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000023780 Quail coronavirus Italy/Elvia/2005 Species 0.000 description 1
- 241000071028 Rabies virus AB21 Species 0.000 description 1
- 241000071026 Rabies virus AB22 Species 0.000 description 1
- 241000071023 Rabies virus BNG4 Species 0.000 description 1
- 241000071027 Rabies virus BNG5 Species 0.000 description 1
- 241000711844 Rabies virus CVS-11 Species 0.000 description 1
- 241000451306 Rabies virus China/DRV Species 0.000 description 1
- 241000451305 Rabies virus China/MRV Species 0.000 description 1
- 241000711841 Rabies virus ERA Species 0.000 description 1
- 241000086082 Rabies virus Eth2003 Species 0.000 description 1
- 241000711839 Rabies virus HEP-FLURY Species 0.000 description 1
- 241000451304 Rabies virus India Species 0.000 description 1
- 241000711851 Rabies virus Nishigahara RCEH Species 0.000 description 1
- 241001502527 Rabies virus Ontario fox Species 0.000 description 1
- 241001529512 Rabies virus Ontario skunk Species 0.000 description 1
- 241000711854 Rabies virus PM Species 0.000 description 1
- 241000712468 Rabies virus SAD B19 Species 0.000 description 1
- 241000451307 Rabies virus silver-haired bat-associated SHBRV Species 0.000 description 1
- 241001428873 Rabies virus strain Street Species 0.000 description 1
- 241000191926 Rabies virus vnukovo-32 Species 0.000 description 1
- 241000920687 Recombinant PIV3/PIV1 virus Species 0.000 description 1
- 241000024242 Reptilian paramyxovirus Species 0.000 description 1
- 241000755299 Restan virus Species 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241000832157 Rio Grande virus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000172807 Rubella virus strain BRD1 Species 0.000 description 1
- 241000172809 Rubella virus strain BRDII Species 0.000 description 1
- 241000710796 Rubella virus strain M33 Species 0.000 description 1
- 241000172802 Rubella virus strain RN-UK86 Species 0.000 description 1
- 241000172803 Rubella virus strain TO-336 Species 0.000 description 1
- 241000710809 Rubella virus strain Therien Species 0.000 description 1
- 208000032108 Russian spring-summer encephalitis Diseases 0.000 description 1
- 241000783706 SFTS virus AH12 Species 0.000 description 1
- 241000783698 SFTS virus AH15 Species 0.000 description 1
- 241000783701 SFTS virus HB29 Species 0.000 description 1
- 241000783692 SFTS virus HN13 Species 0.000 description 1
- 241000783695 SFTS virus HN6 Species 0.000 description 1
- 241000783687 SFTS virus JS3 Species 0.000 description 1
- 241000783689 SFTS virus JS4 Species 0.000 description 1
- 241000783683 SFTS virus LN2 Species 0.000 description 1
- 241000783685 SFTS virus LN3 Species 0.000 description 1
- 241000783681 SFTS virus SD24 Species 0.000 description 1
- 241000783731 SFTS virus SD4 Species 0.000 description 1
- 241000059486 Sabo virus Species 0.000 description 1
- 241000907519 Saboya virus Species 0.000 description 1
- 241000907335 Sal Vieja virus Species 0.000 description 1
- 241000515105 Salem virus Species 0.000 description 1
- 241000618134 Salmo salar paramyxovirus Species 0.000 description 1
- 241000481302 Salmon aquaparamyxovirus Species 0.000 description 1
- 241001379848 Salobo virus Species 0.000 description 1
- 241001135555 Sandfly fever Sicilian virus Species 0.000 description 1
- 241001351366 Sandfly fever Turkey virus Species 0.000 description 1
- 241000120605 Saumarez Reef virus Species 0.000 description 1
- 241000178331 Sepik virus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000059525 Shamonda orthobunyavirus Species 0.000 description 1
- 241000059514 Shuni orthobunyavirus Species 0.000 description 1
- 241001493158 Simbu orthobunyavirus Species 0.000 description 1
- 241001637577 Simian Agent 10 Species 0.000 description 1
- 241001559173 Simian rubulavirus Species 0.000 description 1
- 241001428894 Small ruminant morbillivirus Species 0.000 description 1
- 241000907330 Sokoluk virus Species 0.000 description 1
- 241000436363 Sororoca virus Species 0.000 description 1
- 241000132176 Spanish sheep encephalitis virus Species 0.000 description 1
- 241000907333 Spondweni virus Species 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241001256486 T'Ho virus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000436397 Taiassui virus Species 0.000 description 1
- 241000338155 Tamana bat virus Species 0.000 description 1
- 241000907504 Tembusu virus Species 0.000 description 1
- 241001493143 Tete orthobunyavirus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000448820 Thailand genotype 1 dog lyssavirus Species 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 241001529801 Tick-borne flavivirus Species 0.000 description 1
- 241000932822 Tinaroo virus Species 0.000 description 1
- 241000341969 Tioman virus Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241001434395 Tuhoko virus 1 Species 0.000 description 1
- 241001434392 Tuhoko virus 2 Species 0.000 description 1
- 241001434389 Tuhoko virus 3 Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241001493078 Turlock orthobunyavirus Species 0.000 description 1
- 241001496692 Tursiops truncatus parainfluenza virus 1 Species 0.000 description 1
- 241000120643 Tyuleniy virus Species 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 241000907517 Usutu virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241001441407 Vinces virus Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 241000059484 Yaba-7 virus Species 0.000 description 1
- 241000907505 Yokose virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000005791 algae growth Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001549 bactoprenols Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000008921 border disease Diseases 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 150000002031 dolichols Chemical class 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000612 dual polarization interferometry Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 210000005060 membrane bound organelle Anatomy 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- MZFOKIKEPGUZEN-FBMOWMAESA-N methylmalonyl-CoA Chemical group O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-FBMOWMAESA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006213 negative regulation of lymphocyte proliferation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229930000756 phytoceramide Natural products 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000003097 polyterpenes Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 235000008954 quail grass Nutrition 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 150000003338 secosteroids Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000002657 sphingoid group Chemical group 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical group CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 150000003669 ubiquinones Chemical class 0.000 description 1
- 241001041502 unclassified Respirovirus Species 0.000 description 1
- 241001041505 unclassified Rubulavirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000007656 unidentified coronavirus Species 0.000 description 1
- 241000007181 unidentified human coronavirus Species 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to a use of a peptide, comprising an immune suppressive domain, for introducing entities, such as foreign entities, to cells.
- the invention further relates to a use of a peptide, comprising an immune suppressive domain, for transfection.
- the present invention relates to the use of the peptide for immune suppression in a transfection mix.
- Transfection is the process of deliberately introducing nucleic acids into cells.
- the term is used notably for non-viral methods in eukaryotic cells.
- Transfection is used for the introduction of DNA plasmids into live cells with the purpose of expressing either proteins or silencing / interfering RNA encoded in the plasmid.
- Transfection is also used to introduce immune-stimulatory DNA or RNA into cells with the purpose of studying aspects of immune reactions to DNA or RNA. Further, transfection can be used to introduce non-DNA non-RNA molecules into cells, which directly interfere with cell function.
- the International patent application WO 98/40502 discloses transfection compositions in which a peptide is covalently linked to a transfection agent. The application purports that enhanced transfection efficiency is obtained.
- the International patent application WO 2009/79635 discloses a delivery system for delivering interfering RNA molecules into a cell and methods for using the delivery system.
- Membrane fusion and STING pathway Membrane disturbance as induced by fusion induces type I interferon responses with expression of interferon-stimu!ated genes, in vivo recruitment of leukocytes and potentiation of signaling via Toil- like receptor 7 (TLR7) and TLR9.
- TLR7 Toil- like receptor 7
- the fusion-dependent response is dependent on the stimulator of interferon genes STING.
- Membrane disturbance can be induced by fusion of cellular membranes with viral envelopes, cellular membranes of other cells, and fusogenic liposomes.
- STING stimulation of interferon genes
- M ITA/MPYS/ERIS is also essential for cytosolic DNA-mediated type I IFNs induction.
- STING contains multi-putative transmembrane regions in the amino terminal region, and is found to associate with membranes.
- immune suppressive domains in the viral fusion proteins is expected to insert the immune suppressive activity partly through interference with this pathway either through direct or indirect interaction with STING.
- an antagonist of this putative interaction will enhance the immune responses to proteins containing such immune suppressive domains and can be used as adjuvants.
- fusion proteins typically undergo a conformational transition triggered by receptor recognition or low pH, leading to the insertion of a fusion peptide into the plasma membrane or the membrane of an endocytic vesicle.
- fusion proteins typically include members of the paramyxovirus family, separate envelope proteins mediate attachment and fusion.
- Membrane fusion can occur either at the plasma membrane or at an intracellular location following internalization of virus by receptor-mediated endocytosis. Fusion is mediated by viral
- transmembrane proteins known as fusion proteins.
- the fusion protein interacts with the target membrane through a hydrophobic fusion peptide and undergoes a conformational change that drives the membrane fusion reaction.
- fusion triggers including various combinations of receptor binding, receptor/coreceptor binding, and exposure to the mildly acidic pH within the endocytic pathway. Fusion proteins from different viruses have different names in spite of the common functionality.
- virus membrane fusion proteins are currently annotated to either the "class I" membrane fusion proteins exemplified by the influenza
- hemagglutinin (HA) or HIV-1 gp41 or the "class II" proteins of the alphaviruses and flaviviruses.
- the alphaviruses and flaviviruses are members of the Togaviridae and Flaviviridae families, respectively. These small enveloped positive-sense NAviruses are composed of a capsid protein that assembles with the RNA into the nucleocapsid, and a lipid bilayer containing the viral transmembrane (TM) proteins.
- Class I fusion proteins are synthesized as single chain precursors, which then assemble into trimers.
- the polypeptides are then cleaved by host proteases, which is an essential step in rendering the proteins fusion competent.
- This proteolytic event occurs late in the biosynthetic process because the fusion proteins, once cleaved are metastable and readily activated. Once activated, the protein refolds into a highly stable conformation. The timing of this latter event is of crucial importance in the fusion process. Maintenance of the intact precursor polypeptide during folding and assembly of the oligomeric structure is essential if the free energy that is released during the refolding event is to be available to overcome the inherent barriers to membrane fusion.
- the new amino-terminal region that is created by the cleavage event contains a hydrophobic sequence, which is known as the fusion peptide.
- the authentic carboxy-terminal region of the precursor polypeptide contains the
- transmembrane anchor In the carboxy-terminal polypeptide, there are sequences known as the heptad repeat that are predicted to have an alpha helical structure and to form a coiled coil structure. These sequences participate in the formation of highly stable structure that characterizes the post- fusion conformation of the fusion protein.
- the class II fusion proteins are elongated finger-like molecules with three globular domains composed almost entirely of ⁇ -sheets. Domain I is a ⁇ -barrel that contains the N-terminus and two long insertions that connect adjacent ⁇ -strands and together form the elongated domain II.
- the first of these insertions contains the highly conserved fusion peptide loop at its tip, connecting the c and d ⁇ -strands of domain II (termed the cd loop) and containing 4 conserved disulfide bonds including several that are located at the base of the fusion loop.
- the second insertion contains the ij loop at its tip, adjacent to the fusion loop, and one conserved disulfide bond at its base.
- a hinge region is located between domains I and II.
- a short linker region connects domain I to domain III, a ⁇ -barrel with an immunoglobulin-like fold stabilized by three conserved disulfide bonds.
- domain III is followed by a stem region that connects the protein to the virus TM anchor.
- Fusion peptides are moderately hydrophobic segments of viral and non-viral membrane fusion proteins that enable these proteins to disrupt and connect two closely apposed biological membranes. This process, which results in membrane fusion occurs in a well-controlled manner with a surprisingly small amount of leakage of the contents of the encapsulated volumes to the outside world.
- the sequences of fusion peptides are highly conserved within different groups of fusion proteins, for example within different virus families, but not between them. Most fusion peptides are located at the extreme N-termini of the transmembrane subunits of the fusion proteins.
- Fusion proteins of a subset of enveloped Type I viruses have previously been shown to feature an immune suppressive activity. Inactivated retroviruses are able to inhibit proliferation of immune cells upon stimulation. Expression of these proteins is enough to enable allogenic cells to grow to a tumor in immune competent mice. In one study, introduction of ENV expressing construct into MCA205 murine tumor cells, which do not proliferate upon s.c.
- immunosuppressive domains have been found in a variety of different viruses with type 1 fusion mechanism such as gamma-retroviruses like Mason pfeizer monkey virus (MPMV) and murine leukemia virus (MLV), lentiviruses such as HIV and in filoviruses such as Ebola and Marburg viruses.
- MPMV Mason pfeizer monkey virus
- MMV murine leukemia virus
- lentiviruses such as HIV
- filoviruses such as Ebola and Marburg viruses.
- This immune suppressive activity was in all cases located to a very well-defined structure within the class I fusion proteins, more precisely at the bend in the heptad repeat just N-terminale of the transmembrane structure in the fusion protein.
- the immunosuppressive effects range from significant inhibition of lymphocyte proliferation, cytokine skewing (up regulating IL-10; down regulating TNF-a, IL-12, IFN- ⁇ ) and inhibition of monocytic burst to cytotoxic T cell killing.
- peptides spanning ISD in these assays must either be linked as dimers or coupled to a carrier (i.e. >monomeric) to be active.
- Such peptides derived from immune-suppressive domains are able to reduce or abolish immune responses such as cytokine secretion or proliferation of T-cells upon stimulation.
- the protection mediated by the immunosuppressive properties of the fusion protein from the immune system of the host is not limited to the fusion protein but covers all the viral envelope proteins displayed at viral or cellular membranes in particular also the protein mediating attachment of the virus to the cell.
- immunosuppressive domains of viruses like but not limited to retro-, lenti-, Orthomyxo-, flavi- and filoviruses overlap structurally important parts of the fusion subunits of the surface
- glycoproteins In several cases the primary structure (sequence) of the ISD can vary greatly from virus to virus, but the secondary structure, which is very well preserved among different virus families, is that of an alpha helix that bends in different ways during the fusion process This structure plays a crucial role during events that result in fusion of viral and cellular membranes. It is evident that the immunosuppressive domains of these (retroviral, lentiviral and filoviral) class I fusion proteins overlap with a very important protein structure needed for the fusion mechanistic function.
- the energy needed for mediating the fusion of viral and cellular membranes is stored in the fusion proteins, which are thus found in a meta-stable conformation on the viral surface. Once the energy is released to drive the fusion event, the protein will find its most energetically stable conformation. In this regard fusion proteins can be compared with loaded springs that are ready to be sprung. This high energy conformation makes the viral fusion proteins very susceptible to modifications; Small changes in the primary structure of the protein often result in the protein to be folded in its stable post fusion conformation. The two conformations present very different tertiary structures of the same protein. It has been shown in the case of simple retroviruses that small structural changes in the envelope protein are sufficient to remove the immune suppressive effect without changing structure and hence the antigenic profile.
- the mutated non-immune suppressive envelope proteins are much better antigens for vaccination.
- the proteins can induce a 30-fold enhancement of anti-env antibody titers when used for vaccination and are much better at launching an effective CTL response.
- viruses that contain the non-immunosuppressive form of the friend murine leukemia virus envelope protein although fully infectious in irradiated immunocompromised mice cannot establish an infection in
- Immunosuppressive domains in the fusion proteins have been known since 1985 for retrovirus, since 1988 for lentivirus and since 1992 for filoviruses. These viruses, as mentioned above, all belong to enveloped RNA viruses with a type I fusion mechanism.
- the immunosuppressive domains of lentivirus, retroviruses and filoviruses show large structural similarity. Furthermore the immunosuppressive domain of these viruses are all located at the same position in the structure of the fusion protein, more precisely in the linker between the two heptad repeat structures just N-terminal of the transmembrane domain in the fusion protein.
- the immune suppressive domains can be located in relation to two well conserved cystein residues that are found in these structures. These cystein residues are between 4 and 6 amino acid residues from one another and in many cases are believed to form disulfide bridges that stabilize the fusion proteins.
- the immune suppressive domains in all three cases include at least some of the first 22 amino acids that are located N-terminal to the first cysteine residue.
- Immunosuppressive domains are found in type II fusion proteins. Immunosuppressive domains have been identified at different positions in different groups of viruses. For example an immune suppressive domain might co-localize with the fusion peptide exemplified by the identification of an common immunosuppressive domain in the fusion peptide of Flavirius (Dengue virus, west Nile virus etc), or with the hydrophobic alpha helix N-terminal of the transmembrane domain in the fusion protein exemplified by the finding of an immunosuppressive domain in said helixes of all flaviridae e.g. Hepatitis C virus, Dengue, west nile etc.
- flaviridae e.g. Hepatitis C virus, Dengue, west nile etc.
- the immune suppressive domains can also be located in the fusion peptide of the fusion protein among enveloped RNA viruses with type I fusion mechanism.
- HIV or influenza A and B types have an immune suppressive domain that co-localized with their fusion peptide.
- immunosuppressive domains are identified among enveloped RNA viruses with type II fusion mechanism at different positions in different groups of viruses: i. Co-localizing with the fusion peptide exemplified by the identification of an common
- Immunosuppressive domains have been identified in the fusion protein among enveloped RNA viruses with type I fusion mechanism. This position co-localizes with the fusion peptide of said fusion protein as demonstrated by the identification of a common immunosuppressive domain in the fusion peptide of all Influenza A and B types as well as HIV.
- Functional homolog refers to homologues of the molecules according to the present invention and is meant to comprise any molecule which is capable of mimicking the function of molecules as described herein. Thus, the terms refer to functional similarity or, interchangeably, functional identity, between two or more molecular entities.
- functional homology is further used herein to describe that one molecular entity are able to mimic the function of one or more molecular entities.
- Functional homologues according to the present invention may comprise any molecule that can function as an antagonist of the immune suppressive activity exerted by an immune suppressive domains.
- a molecule when added to the composition containing said immune suppressive domains reduces the immune suppressive activity exerted by the latter in either an in vitro test system (e.g. CTLL-2 or PBMC proliferation assays) or in vivo seen as an enhanced T- and/or B-cell responses.
- Functional homologues according to the present invention may comprise polypeptides with an amino acid sequence, which are sharing at least some homology with the predetermined polypeptide sequences as outlined herein.
- polypeptides are at least about 40 percent, such as at least about 50 percent homologous, for example at least about 60 percent homologous, such as at least about 70 percent homologous, for example at least about 75 percent homologous, such as at least about 80 percent homologous, for example at least about 85 percent homologous, such as at least about 90 percent homologous, for example at least 92 percent homologous, such as at least 94 percent homologous, for example at least 95 percent homologous, such as at least 96 percent homologous, for example at least 97 percent homologous, such as at least 98 percent homologous, for example at least 99 percent homologous with the predetermined polypeptide sequences as outlined herein above.
- the homology between amino acid sequences may be calculated using well known algorithms such as for example any one of BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, and BLOSUM 90.
- Functional homologues may comprise an amino acid sequence that comprises at least one substitution of one amino acid for any other amino acid.
- a substitution may be a conservative amino acid substitution or it may be a non-conservative substitution.
- a conservative amino acid substitution is a substitution of one amino acid within a predetermined group of amino acids for another amino acid within the same group, wherein the amino acids within predetermined groups exhibit similar or substantially similar characteristics.
- one amino acid may be substituted for another within groups of amino acids characterized by having i) hydrophilic (polar) side chains (Asp, Glu, Lys, Arg, His, Asn, Gin, Ser, Thr, Tyr, and Cys,) ⁇ ) hydrophobic (non-polar) side chains (Gly, Ala, Val, Leu, lie, Phe, Trp, Pro, and Met) iii) aliphatic side chains (Gly, Ala Val, Leu, lie)
- amino acids being monoamino-dicarboxylic acids or monoamino-monocarboxylic- monoamidocarboxylic acids (Asp, Glu, Asn, Gin).
- Non-conservative substitutions are any other substitutions.
- a non-conservative substitution leading to the formation of a functional homologue would for example i) differ substantially in hydrophobicity, for example a hydrophobic residue (Val, lie, Leu, Phe or Met) substituted for a hydrophilic residue such as Arg, Lys, Trp or Asn, or a hydrophilic residue such as Thr, Ser, His, Gin, Asn, Lys, Asp, Glu or Trp substituted for a hydrophobic residue; and/or ii) differ substantially in its effect on polypeptide backbone orientation such as substitution of or for Pro or Gly by another residue; and/or iii) differ substantially in electric charge, for example substitution of a negatively charged residue such as Glu or Asp for a positively charged residue such as Lys, His or Arg (and vice versa); and/or iv) differ substantially in steric bulk, for example substitution of a bulky residue such as His, Trp, Phe or Tyr for one having
- Functional homologues according to the present invention may comprise more than one such substitution, such as e.g. two amino acid substitutions, for example three or four amino acid substitutions, such as five or six amino acid substitutions, for example seven or eight amino acid substitutions, such as from 10 to 15 amino acid substitutions, for example from 15 to 25 amino acid substitution, such as from 25 to 30 amino acid substitutions, for example from 30 to 40 amino acid substitution, such as from 40 to 50 amino acid substitutions, for example from 50 to 75 amino acid substitution, such as from 75 to 100 amino acid substitutions, for example more than 100 amino acid substitutions.
- substitutions such as e.g. two amino acid substitutions, for example three or four amino acid substitutions, such as five or six amino acid substitutions, for example seven or eight amino acid substitutions, such as from 10 to 15 amino acid substitutions, for example from 15 to 25 amino acid substitution, such as from 25 to 30 amino acid substitutions, for example from 30 to 40 amino acid substitution, such as from 40 to 50 amino acid substitutions, for example from 50 to 75 amino acid substitution,
- the addition or deletion of an amino acid may be an addition or deletion of from 2 to 5 amino acids, such as from 5 to 10 amino acids, for example from 10 to 20 amino acids, such as from 20 to 50 amino acids.
- additions or deletions of more than 50 amino acids, such as additions from 50 to 200 amino acids are also comprised within the present invention.
- polypeptides according to the present invention may in one embodiment comprise more than 5 amino acid residues, such as more than 10 amino acid residues, for example more than 20 amino acid residues, such as more than 25 amino acid residues, for example more than 50 amino acid residues, such as more than 75 amino acid residues, for example more than 100 amino acid residues, such as more than 150 amino acid residues, for example more than 200 amino acid residues.
- the genetic code is the set of rules by which information encoded within genetic material (DNA or m NA sequences) is translated into proteins (amino acid sequences) by living cells. Biological decoding is accomplished by the ribosome, which links amino acids in an order specified by mRNA, using transfer RNA (tRNA) molecules to carry amino acids and to read the mRNA three nucleotides at a time.
- tRNA transfer RNA
- the code defines how sequences of these nucleotide triplets, called codons, specify which amino acid will be added next during protein synthesis. With some exceptions a three-nucleotide codon in a nucleic acid sequence specifies a single amino acid. Because the vast majority of genes are encoded with exactly the same code (see the RNA codon table), this particular code is often referred to as the canonical or standard genetic code, or simply the genetic code, though in fact some variant codes have evolved. For example, protein synthesis in human mitochondria relies on a genetic code that differs from the standard genetic code. Not all genetic information is stored using the genetic code.
- All organisms' DNA contains regulatory sequences, intergenic segments, chromosomal structural areas, and other non-coding DNA that can contribute greatly to phenotype. Those elements operate under sets of rules that are distinct from the codon-to-amino acid paradigm underlying the genetic code.
- Codons Compressed Codons Compressed acid acid
- GCU GCC, GCA, UUA, UUG, CUU,
- ACU ACC, ACA,
- L-amino acids represent all of the amino acids found in proteins during translation in the ribosome
- D-amino acids are found in some proteins produced by enzyme posttranslational modifications after translation and translocation to the endoplasmic reticulum, as in exotic sea-dwelling organisms such as cone snails. They are also abundant components of the peptidoglycan cell walls of bacteria, and D-serine may act as a neurotransmitter in the brain.
- L and D convention for amino acid configuration refers not to the optical activity of the amino acid itself, but rather to the optical activity of the isomer of
- glyceraldehyde from which that amino acid can, in theory, be synthesized (D-glyceraldehyde is dextrorotary; L-glyceraldehyde is levorotatory).
- Fatty acids, or fatty acid residues when they form part of a lipid are a diverse group of molecules synthesized by chain-elongation of an acetyl-CoA primer with malonyl-CoA or methylmalonyl-CoA groups in a process called fatty acid synthesis. They are made of a hydrocarbon chain that terminates with a carboxylic acid group; this arrangement confers the molecule with a polar, hydrophilic end, and a nonpolar, hydrophobic end that is insoluble in water.
- the fatty acid structure is one of the most fundamental categories of biological lipids, and is commonly used as a building-block of more structurally complex lipids.
- the carbon chain typically between four and 24 carbons long, may be saturated or unsaturated, and may be attached to functional groups containing oxygen, halogens, nitrogen, and sulfur.
- a double bond exists, there is the possibility of either a cis or trans geometric isomerism, which significantly affects the molecule's configuration.
- Cis-double bonds cause the fatty acid chain to bend, an effect that is compounded with more double bonds in the chain. This in turn plays an important role in the structure and function of cell membranes.
- Most naturally occurring fatty acids are of the cis configuration, although the trans form does exist in some natural and partially hydrogenated fats and oils.
- biologically important fatty acids are the eicosanoids, derived primarily from arachidonic acid and eicosapentaenoic acid, that include prostaglandins, leukotrienes, and thromboxanes.
- Docosahexaenoic acid is also important in biological systems, particularly with respect to sight.
- Other major lipid classes in the fatty acid category are the fatty esters and fatty amides.
- Fatty esters include important biochemical intermediates such as wax esters, fatty acid thioester coenzyme A derivatives, fatty acid thioester ACP derivatives and fatty acid carnitines.
- the fatty amides include N-acyl ethanolamines, such as the cannabinoid neurotransmitter anandamide.
- Glycerolipids are composed mainly of mono-, di-, and tri-substituted glycerols, the most well-known being the fatty acid triesters of glycerol, called triglycerides.
- the word "triacylglycerol” is sometimes used synonymously with "triglyceride", though the latter lipid contains no hydroxyl group.
- the three hydroxyl groups of glycerol are each esterified, typically by different fatty acids. Because they function as an energy store, these lipids comprise the bulk of storage fat in animal tissues.
- the hydrolysis of the ester bonds of triglycerides and the release of glycerol and fatty acids from adipose tissue are the initial steps in metabolising fat.
- glycosylglycerols are characterized by the presence of one or more sugar residues attached to glycerol via a glycosidic linkage.
- structures in this category are the digalactosyldiacylglycerols found in plant membranes and seminolipid from mammalian sperm cells.
- Glycerophospholipids usually referred to as phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and cell signaling.
- Neural tissue including the brain contains relatively high amounts of glycerophospholipids, and alterations in their composition has been implicated in various neurological disorders.
- Glycerophospholipids may be subdivided into distinct classes, based on the nature of the polar headgroup at the sn-3 position of the glycerol backbone in eukaryotes and eubacteria, or the sn-1 position in the case of archaebacteria.
- Examples of glycerophospholipids found in biological membranes are phosphatidylcholine (also known as PC, GPCho or lecithin), phosphatidylethanolamine (PE or GPEtn) and phosphatidylserine (PS or GPSer).
- glycerophospholipids in eukaryotic cells such as phosphatidylinositols and phosphatidic acids are either precursors of or, themselves, membrane- derived second messengers.
- phosphatidylinositols and phosphatidic acids are either precursors of or, themselves, membrane- derived second messengers.
- one or both of these hydroxyl groups are acylated with long- chain fatty acids, but there are also alkyl-linked and lZ-alkenyl-linked (plasmalogen)
- glycerophospholipids as well as dialkylether variants in archaebacteria.
- Sphingolipids are a complicated family of compounds that share a common structural feature, a sphingoid base backbone that is synthesized de novo from the amino acid serine and a long-chain fatty acyl CoA, then converted into ceramides, phosphosphingolipids, glycosphingolipids and other compounds.
- the major sphingoid base of mammals is commonly referred to as sphingosine.
- Ceramides are a major subclass of sphingoid base derivatives with an amide-linked fatty acid.
- the fatty acids are typically saturated or mono-unsaturated with chain lengths from 16 to 26 carbon atoms.
- the major phosphosphingolipids of mammals are sphingomyelins (ceramide phosphocholines), whereas insects contain mainly ceramide phosphoethanolamines and fungi have phytoceramide phosphoinositols and mannose-containing headgroups.
- the glycosphingolipids are a diverse family of molecules composed of one or more sugar residues linked via a glycosidic bond to the sphingoid base. Examples of these are the simple and complex glycosphingolipids such as cerebrosides and gangliosides.
- Sterol lipids such as cholesterol and its derivatives, are an important component of membrane lipids, along with the glycerophospholipids and sphingomyelins.
- the steroids all derived from the same fused four-ring core structure, have different biological roles as hormones and signaling molecules.
- the eighteen-carbon (C18) steroids include the estrogen family whereas the C19 steroids comprise the androgens such as testosterone and androsterone.
- the C21 subclass includes the progestogens as well as the glucocorticoids and mineralocorticoids.
- the secosteroids comprising various forms of vitamin D, are characterized by cleavage of the B ring of the core structure.
- sterols are the bile acids and their conjugates, which in mammals are oxidized derivatives of cholesterol and are synthesized in the liver.
- the plant equivalents are the phytosterols, such as ⁇ -sitosterol, stigmasterol, and brassicasterol; the latter compound is also used as a biomarker for algal growth.
- the predominant sterol in fungal cell membranes is ergosterol.
- Prenol lipids are synthesized from the five-carbon-unit precursors isopentenyl diphosphate and dimethylallyl diphosphate that are produced mainly via the mevalonic acid (MVA) pathway.
- the simple isoprenoids (linear alcohols, diphosphates, etc.) are formed by the successive addition of C5 units, and are classified according to number of these terpene units. Structures containing greater than 40 carbons are known as polyterpenes.
- Carotenoids are important simple isoprenoids that function as antioxidants and as precursors of vitamin A.
- quinones and hydroquinones which contain an isoprenoid tail attached to a quinonoid core of non-isoprenoid origin.
- Vitamin E and vitamin K as well as the ubiquinones, are examples of this class.
- Prokaryotes synthesize polyprenols (called bactoprenols) in which the terminal isoprenoid unit attached to oxygen remains unsaturated, whereas in animal polyprenols (dolichols) the terminal isoprenoid is reduced.
- Saccharolipids describe compounds in which fatty acids are linked directly to a sugar backbone, forming structures that are compatible with membrane bilayers.
- a saccharolipid In the saccharolipids, a
- glycerophospholipids The most familiar saccharolipids are the acylated glucosamine precursors of the Lipid A component of the lipopolysaccharides in Gram-negative bacteria. Typical lipid A molecules are disaccharides of glucosamine, which are derivatized with as many as seven fatty-acyl chains.
- the minimal lipopolysaccharide required for growth in E. coli is Kdo2-Lipid A, a hexa-acylated disaccharide of glucosamine that is glycosylated with two 3-deoxy-D-manno-octulosonic acid (Kdo) residues.
- Polyketides are synthesized by polymerization of acetyl and propionyl subunits by classic enzymes as well as iterative and multimodular enzymes that share mechanistic features with the fatty acid synthases. They comprise a large number of secondary metabolites and natural products from animal, plant, bacterial, fungal and marine sources, and have great structural diversity. Many polyketides are cyclic molecules whose backbones are often further modified by glycosylation, methylation, hydroxylation, oxidation, and/or other processes.
- anti-microbial, anti-parasitic, and anti-cancer agents are polyketides or polyketide derivatives, such as erythromycins, tetracyclines, avermectins, and antitumor epothilones.
- the glycerophospholipids are the main structural component of biological membranes, such as the cellular plasma membrane and the intracellular membranes of organelles; in animal cells the plasma membrane physically separates the intracellular components from the extracellular environment.
- the glycerophospholipids are amphipathic molecules (containing both hydrophobic and hydrophilic regions) that contain a glycerol core linked to two fatty acid-derived "tails" by ester linkages and to one "head” group by a phosphate ester linkage. While
- glycerophospholipids are the major component of biological membranes, other non-glyceride lipid components such as sphingomyelin and sterols (mainly cholesterol in animal cell membranes) are also found in biological membranes.
- sphingomyelin and sterols mainly cholesterol in animal cell membranes
- galactosyldiacylglycerols, and sulfoquinovosyldiacylglycerol which lack a phosphate group, are important components of membranes of chloroplasts and related organelles and are the most abundant lipids in
- Bilayers have been found to exhibit high levels of birefringence, which can be used to probe the degree of order (or disruption) within the bilayer using techniques such as dual polarization interferometry and Circular dichroism.
- a biological membrane is a form of lipid bilayer.
- the formation of lipid bilayers is an energetically preferred process when the glycerophospholipids described above are in an aqueous environment. This is known as the hydrophobic effect.
- the hydrophobic tails minimize their contact with water and tend to cluster together, forming a vesicle; depending on the concentration of the lipid, this biophysical interaction may result in the formation of micelles, liposomes, or lipid bilayers.
- Other aggregations are also observed and form part of the polymorphism of amphiphile (lipid) behavior.
- Phase behavior is an area of study within biophysics and is the subject of current academic research.
- Micelles and bilayers form in the polar medium by a process known as the hydrophobic effect.
- the polar molecules i.e., water in an aqueous solution
- the polar molecules become more ordered around the dissolved lipophilic substance, since the polar molecules cannot form hydrogen bonds to the lipophilic areas of the amphiphile. So in an aqueous environment, the water molecules form an ordered "clathrate" cage around the dissolved lipophilic molecule.
- the present invention concerns a use of a peptide, comprising an immune suppressive domain, for transfection.
- the invention concerns a use of a peptide comprising an immune suppressive domain for transfection, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, subject to the proviso that a monomeric peptide should comprise at least two immune suppressive domain sequences.
- the invention concerns a use of a peptide comprising an immune suppressive domain in a transfection mix, subject to the proviso that said peptide is a dimer or multimer or comprises at least two immune suppressive domain motifs.
- a dimer or multimer may comprise more than one immune suppressive domain motif.
- the invention concerns a use of a peptide comprising an immune suppressive domain for transfection of a cell, said peptide providing immune suppression of the transfected cell.
- the invention concerns a use of a molecule, which comprises at least two parts, each part comprising an immune suppressive domain, for transfection.
- the invention concerns a kit-of-parts or composition comprising: a. a transfection agent; and b. a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a transfection reagent comprising a lipid based molecule coupled covalentely to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a nano particle coupled covalentely to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a hydrophobic vehicle for delivery of hydrophobic molecules coupled covalently to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a drug coupled covalently to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a use of a peptide, composition, a kit-of-parts, a transfection agent, a nano particle, a hydrophobic vehicle or a drug according to the invention for inhibiting immune response.
- the invention concerns a method for transfecting a cell, said method comprising: a. Providing a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences; b. Incubating the cell with said peptide; c. Providing a transfection agent; d. Providing a material to be transfected into the cell; and e. Further incubating the cell with said transfection agent and said material.
- the invention concerns a cell obtainable with said method for transfecting a cell.
- the invention concerns a cell obtainable by incubating a cell with a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a cell comprising a peptide, said peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a use of a cell according to the invention, for diagnostics, prophylaxis or therapy.
- the present invention concerns a use of a peptide, comprising an immune suppressive domain, for transfection.
- Transfection is the process of deliberately introducing nucleic acids into cells.
- the term "for transfection” is meant to encompass that the peptide is used as part of the transfection process, for example together with at least one transfection agent, and/or for preparing a cell for additional steps of the transfection process.
- immune suppressive activity means that it can inhibit proliferation of CTLL-2 or PBMCs in assays as described in the examples, i.e. by more than 20% or interfere with type I IFN production in response to lipid based formulations.
- the invention concerns a use of a peptide comprising an immune suppressive domain for transfection, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, subject to the proviso that a monomeric peptide should comprise at least two immune suppressive domain sequences.
- peptide as used here, comprises shorter amino sequences as well as longer sequences such as proteins, and monomers as well as dimers and multimers.
- the immune suppressive peptides do not need to be covalently bound to form a dimer or multimer. If they contain multimerization domains, the monomeric peptides may associate together through non-covalent interactions and form dimers or multimers that will also be functional.
- the invention concerns the use of a peptide of the invention, wherein said peptide is a dimer.
- the invention concerns a use of a peptide comprising an immune suppressive domain in a transfection mix, subject to the proviso that said peptide is a dimer or multimer or comprises at least two immune suppressive domain motifs.
- the word "or” is not necessarily an exclusive expression.
- a dimer or multimer may comprise more than one immune suppressive domain motif, and still be within the scope of the present invention.
- the invention concerns the use of the invention, wherein said at least two immune suppressive domain motifs are two identical or different motifs.
- the invention concerns a use of a peptide comprising an immune suppressive domain for transfection of a cell, said peptide providing immune suppression of the transfected cell.
- the invention concerns the use of a peptide according to the invention, which is soluble in water.
- the peptide is preferably sufficiently soluble to provide immune suppressive activity in an aqueous solution.
- the invention concerns the use of a peptide according to the invention, wherein said immune suppressive domain is part of a virus.
- the invention concerns the use of a peptide of the invention, wherein said virus is an influenza virus.
- the invention concerns the use of a peptide according to the invention, wherein said peptide forms part of a protein.
- the invention concerns a use of a molecule, which comprises at least two parts, each comprising an immune suppressive domain, for transfection.
- the invention concerns a kit-of-parts or composition comprising: a. a transfection agent; and b. a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns the kit-of-parts or composition of the invention, wherein said transfection agent is coupled covalentely to said peptide.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said transfection agent is a lipid based transfection agent.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said lipid based transfection agent is selected among an anionic and a cationic transfection agent.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said transfection agent is a lipid based liposome or virosome or viral vector.
- the invention concerns the kit-of-parts or composition according to the invention, comprising a nano particle.
- a nanoparticle may e.g. be used for drug delivery, it may have an inherent therapeutic effect, or it may be fluorescent and used for tests.
- the invention concerns the kit-of-parts or composition according to the invention, further comprising a hydrophobic vehicle for delivery of hydrophobic molecules.
- the invention concerns the kit-of-parts or composition according to the invention, comprising a drug.
- the immune suppressive domain may suppress an unwanted immune response induced by the drug, which e.g. may comprise a carrier oil, known to induce an immune response.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is an immune suppressive peptide.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide forms part of a protein of a pathogen.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said pathogen is a virus.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide forms part of a protein on the surface of a pathogen.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide forms part of a virus surface glycoprotein.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said immune suppressive peptide forms part of an enveloped virus surface glycoprotein.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said immune suppressive peptide has a length of at least 6, preferably 7, more preferred 8, preferably 9, more preferred 10, preferably 11, more preferred 12, preferably 13, more preferred 14, preferably 15, more preferred 16, preferably 17, more preferred 18, preferably 19, more preferred 20, preferably 21 more preferred 22, preferably 23, more preferred 24, preferably 25 amino acids.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide has a length selected among 5 - 200, preferably 10 - 100, more preferred 20 - 50, preferably 30 - 40 amino acids.
- the invention concerns the kit-of-parts or composition according to the invention, further comprising a fusion peptide from a fusion protein.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said fusion peptide is from the fusion protein of an enveloped virus.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said fusion peptide is from a type I fusion protein.
- the invention concerns the kit-of-parts or composition according to the invention, comprising a fusion peptide from a type II fusion protein.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said fusion peptide has 1, 2, 3 or 4 mutations, deletions or insertions with respect to the wild type.
- mutation is used with a number about this number of point mutation(s), i.e. 3 mutations mean 3 point mutations.
- deletion is used with a number about the deletion of this number of amino acid(s), i.e. 2 deletions means the deletion of 2 amino acids.
- insertion is used with a number about insertion of this number of amino acid(s), i.e. 1 insertion means the insertion of 1 amino acid.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide, or a functional homologue thereof, binds either directly or indirectly to a cellular protein complex containing the protein STING encoded by the gene Tmeml73.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide, or a functional homologue thereof, affects type I interferon responses.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide, or a functional homologue thereof, affects type I interferon responses induced by membrane fusion.
- the invention concerns the kit-of-parts or composition according to the invention, comprising a peptide from selected among the group consisting of the lists of Table 1 and among the sequences with Seq. Id. 1 - 287.
- the invention concerns the kit-of-parts or composition according to the invention, comprising a peptide from an influenza virus or a Flu peptide.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide has immune suppressive activity as dimer or mulitimer or when coupled to carrier proteins.
- the coupling of peptides to larger proteins is one of the known methods for producing mulitimeric peptides or antigens.
- Proteins such as Bovine serum albumin (BSA) or Keyhole limpet hemocyanin (KLH) can be used as carrier proteins.
- BSA Bovine serum albumin
- KLH Keyhole limpet hemocyanin
- KLH is used extensively as a carrier protein in the production of antibodies for research
- KLH is an effective carrier protein for several reasons. Its large size and numerous epitopes generate a substantial immune response, and abundance of lysine residues used as coupling sites.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide comprises at least one non-genetically encoded amino acid residue.
- the non-genetically encoded amino acid residues are amino acid residues, which are not genetically encoded.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide comprises at least one D-amino acid. According to an embodiment, the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide comprises at least one D-amino acid residue.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is coupled to any other molecule.
- Two peptides may be joined via another molecule, and each of the two peptides may comprise an immune suppressive domain sequence.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is attached to lipids.
- Lipids are here defined as cationic, anionic or neutrally charged fatty acids and their derivatives (including tri-, di-, monoglycerides, and phospholipids), as well as sterol-containing metabolites such as cholesterol).
- Liposomes may be used as a delivery system, and vesicles may be at least partly covered by immune suppressive domains, thereby suppressing a potential immune system response to the delivery system.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is coupled to a molecule through a peptide bond.
- the molecule may e.g. be a ligand of a receptor, thereby targeting the peptide, or it may e.g. be a molecule providing different solubility characteristics of the combination of the peptide and the molecule as compared to the peptide alone, or the molecule may be a nanoparticle.
- the peptide may further form part of a protein, which may provide advantages such as easy production, as the protein may be derived from natural sources.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is coupled to a protein.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is a circular peptide.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is attached to at least one biological membrane.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide is modified in a way in which one of the peptide bonds is replaced by a non-peptide bond.
- the invention concerns the kit-of-parts or composition according to the invention, wherein said peptide interferes with an interferon response induced by the transfection agent upon addition to a cell.
- the invention concerns the kit-of-parts or composition comprising a functional homologue of a peptide according to the invention.
- a functional homologue may be replaced by an altered peptide, obtained from a peptide of the invention, by making 1, 2, 3, or 4 mutations, deletions or insertions of the immune suppressive domain.
- An alternated peptide may have a %identity vis-a-vis the unaltered form of at least 60%, preferably at least 70%, more preferred at least 80%, preferably at least 90%, more preferred at least 95%, preferably at least 98%, more preferred at least 99%.
- the invention concerns a transfection reagent comprising a lipid based molecule coupled covalentely to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a nano particle coupled covalentely to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a hydrophobic vehicle for delivery of hydrophobic molecules coupled covalently to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a drug coupled covalently to a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the invention concerns a use of a peptide, composition, a kit-of-parts, a transfection agent, a nano particle, a hydrophobic vehicle or a drug according to the invention for inhibiting immune response.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention for introducing a molecule into a cell.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention, for introducing a DNA or NA molecule into a cell.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention, for introducing a pharmaceutical molecule into a cell.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention, for introducing a pharmaceutical molecule into a tissue.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention, for introducing a gene-therapeutic pharmaceutical molecule into a cell.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention for initiating expression of proteins via transfected plasmids. According to an embodiment, the invention concerns the use of a peptide, composition, or a kit of parts according to the invention for targeting active genes by micro NA silencing.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention for examining the immune response to DNA or RNA. According to an embodiment, the invention concerns the use of a peptide, composition, or a kit of parts according to the invention for gene therapy.
- the invention concerns the use of a peptide, composition, or a kit of parts according to the invention for delivery of any molecule using liposomes.
- the invention concerns a method for transfecting a cell, said method comprising: a. Providing a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences; b. Incubating the cell with said peptide; c. Providing a transfection agent; d. Providing a material to be transfected into the cell; and e. Further incubating the cell with said transfection agent and said material.
- the invention concerns a cell obtainable with said method for transfecting a cell.
- the cells obtainable by this process produce less or no cytokines, in particular interferons, compared to cells obtained without the use of the peptides of the invention. I.e. when compared to untreated cells, cells treated with the INF-F#2 peptide produce less or no cytokines, in particular interferons, but appear to retain the ability to react to other and stronger stimuli.
- the invention concerns a cell obtainable by incubating a cell with a peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences. Such a cell may be used e.g.
- the invention concerns a cell comprising a peptide, said peptide comprising an immune suppressive domain, wherein said peptide is selected among a dimer, a multimer, and a monomeric peptide, which comprises at least two immune suppressive domain sequences.
- the peptide may e.g. be bound to the surface of the cell, internally or externally, or may be present inside of the cell.
- the invention concerns a use of a cell according to the invention, for diagnostics, prophylaxis or therapy.
- the invention concerns the use according to the invention, for cell therapy and/or gene therapy.
- Gene therapy and cell therapy are overlapping fields of biomedical research with similar therapeutic goals.
- Gene therapy can be defined as the use of genetic material (usually deoxyribonucleic acid - DNA) to manipulate a patient's cells for the treatment of an inherited or acquired disease.
- Cell Therapy can be defined as the infusion or transplantation of whole cells into a patient for the treatment of an inherited or acquired disease.
- the invention concerns the use according to the invention, for stem cell transplantation.
- Table 1 is provided below. Table 1 likewise provides a number of immunosuppressive domains and motifs.
- Flavivirus sp Flavivirus sp .
- Hepa Hepatitis C Hepatitis C virus genotype 1 a seqid3
- Border disease virus 2 SYFQQYMLKGQYQYWFDLE
- Rubella virus strain TO-336 MSVFALASYVQHPHKTVRVKFHT vaccine .
- Phlebovirus JS24 Phlebovirus JS24
- Phlebovir sp Phlebovir sp .
- Bovine parainfluenza virus 3 Porcine paramyxovirus strain Frost Porcine paramyxovirus strain Texas Human parainfluenza virus 1 Human parainfluenza virus 3 Simian Agent 10
- Tuhoko virus 3 unclassified Atlantic salmon paramyxovirus Paramyxovirinae Beilong virus
- the I N F-F#2 peptide has the sequence GLFGAIAGFI ENGWEGCGGEKEKEK [Seq id 287] and is dimerized through a disulfide bridge between the cystein residues.
- Fig. 1 shows type I IFN production in cells either untreated (UT) or treated with cationic liposomes.
- Cells were either pre-treated with IN F-F#2 or not pre-treated with any substance.
- treatment with cationic liposomes induce the production of type I I FN and that this production was inhibited when cells were pre-treated with IN F-F#2.
- the cells used were bonemarrow derived dendritic cells (BM DCs) from mice of the laboratory strain C57BL.
- the peptide IN F-F#2 was used at a concentration of ⁇ and initiated 15minutes before treatment with cationic liposomes.
- Cells were then left to incubate 16 hours at 5% C0 2 and 37.5 degrees Celcius. After 16 hours of incubation the supernatants were harvested. Type I I FN activity was then measured using a type I I FN bioassay.
- Cationic liposomes were prepared using a mix of the lipids DOTAP/DOPE/L (Lissamine Rhodamine)- DOPE in a w/w/w of 1/1/0.1 dissolved in chloroform.
- the mix was purchased from the company Avanti Polar Lipids, inc. Chloroform was evaporated using rotation evaporation using a dry nitrogen stream. The lipids film was then dried in vaccum for 4 hours. To created liposomes, the lipid film was hydrated in phosphate buffered saline solution at pH 7.4 at ambient temperature. Liposomes were then size restricted using a 0.2 ⁇ filter and an Avanti Mini-extruder purchased form Avanti Polar Lipids. Fig.
- FIG. 2 shows type I I FN production in cells either untreated (UT) or treated with the transfection reagent Lipofectamine2000 (Lipofect) according to the manufactures instructions.
- Lipofectamine2000 was used alone and not with the purpose of transfecting DNA or RNA into the cells.
- the type I IFN produces therefore represent the cellular response to the transfection reagent Lipofectamine2000 itself.
- Cells were either pre-treated with IN F-F#2 or not pre-treated with any substance.
- treatment with Lipofectamine2000 induced the production of type I IFN and that this production was inhibited when cells were pre-treated with IN F-F#2.
- Cells used were BM DCs as described in the Figure 1 text.
- Fig. 3 shows type I IFN production in cells either untreated (UT) or transfected with double stranded DNA (dsDNA) using the reagent Lipofectamine2000 according to the manufactures instructions.
- Cells were either pre-treated with IN F-F#2 or not pre-treated with any substance.
- transfection with dsDNA induces the production of type I IFN and that this production was NOT inhibited when cells were pre-treated with IN F-F#2. Therefore, pretreatment does not interfere with type I I FN levels induced by the transfected dsDNA but only with the type I I FN induced by the transfection reagent itself.
- Cells used were BM DCs as described in the Figure 1 text.
- Beads were then collected by centrifugation at 2000xg for 2min. Beads were then washed x3 in PBS at pH 7.4. Beads were then headed to 95 deg. Celcius in reducing denaturating loading buffer for 5 min. yielding the pull-down lysate. This was then loaded and run on a SDS-PAGE for 45 min at 120V. Proteins were then transferred to protein PVDF membrane and blotted for STING and Giantin. The protein Giantin is a golgi-resident transmembrane protein unrelated to STING function. As depicted in figure 4, the INF-F#2 but not beads alone or the peptide DI6 was able to precipitate STING. Further, INF-F#2 was unable to precipitate other transmembrane proteins such as Giantin.
- the peptide INF-F#2 therefore blocks STING dependent type I IFN production in response to membrane disturbance as introduced by liposome based transfection agents. This is possibly through direct or indirect interaction with STING itself as INF-F#2 binds either directly to STING or to a complex which contains STING. This occurs without significant interference with type I IFN production with response to transfected immuno-stimulatory DNA itself (Fig. 3)
- Fig. 5 shows the effect of INF-F#2 (INF ISD) on STING dimerization in response to cationic liposomes.
- Cells of the human moncytic cell line THP-1 were either culture in the presence or absence of INF-F#2 (INF ISD) as depicted. Cells were then either treated with or left untreated with cationic liposomes (as in Figure 1) for 3.5 hours. Cells were then lysed using IPA lysis buffer with
- Pretreatment of cells with INF-F#2 resultet in an inhibition of the formation of STING dimers.
- Light panel Lysates from cells treated with cationic liposomes either treated with the reducing agent DTT or left untreated for 5min.
- INF-F#2 binds either directly to STING or to a STING containing complex ( Figure 4), and interferes with STING dimerization in response to cellular treatment with cationic liposomes.
- Figure 6 shows inflammation-related enzyme and transcription factor gene expression kinetics of THP-1 monocytes stimulated with ⁇ g/ml LPS. Gene expression was expressed as relative gene expression towards RPL13a-expression and non-stimulated cells at time zero (AACt). Data shown are means + standard deviation from two independent biological replications.
- FIG. 7 shows effects of INF-F#2 peptide on expression of NF-kappaB mRNA in LPS-stimulated THP-1 cells.
- THP-1 cells were incubated with either medium alone, 30 ⁇ , 60 ⁇ INF-F#2 peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS. Data shown are the medians ⁇ standard deviation from two independent biological replications.
- FIG. 8 shows effects of INF-F#2 peptide on expression of SP-1 mRNA in LPS-stimulated THP-1 cells.
- THP-1 cells were incubated with either medium alone, 30 ⁇ , 60 ⁇ INF-F#2 peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS. Data shown are the medians ⁇ standard deviation from two independent biological replications.
- FIG 9 shows effects of INF-F#2 peptide on protein secretion of IL-8 in LPS-stimulated THP-1 cells.
- THP-1 cells were incubated with either medium alone, 30 ⁇ or 60 ⁇ INF-F#2 peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS. Data shown are the median ⁇ standard deviation from three independent experiments performed in duplicates.
- Figure 10 shows effects of INF-F#2 peptide on protein secretion of IL-10 in LPS-stimulated THP-1 cells. THP-1 cells were incubated with either medium alone, 30 ⁇ or 60 ⁇ INF-F#2 peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS.
- Figure 12 shows expression kinetics of IFN gamma expression in response to PMA/ionomycin treatment. Gene expression was expressed as relative gene expression towards RPL13a expression and non-stimulated cells at time zero ( ⁇ Ct). Data shown are the medians ⁇ standard deviation from three independent technical replicates.
- Figure 13 shows effect of INF-F#2 peptide on secretion of protein of IFN-gamma in PMA/ionomycin stimulated PBMCs.
- PBMCs were incubated with either medium alone, 30 ⁇ or 60 ⁇ INF-F#2 peptide or 30 ⁇ or 60 ⁇ control peptide, and stimulated with 50ng/ml PMA and ⁇ g/ml ionomycin.
- Data shown are the medians ⁇ standard deviation from three independent experiments performed in duplicates.
- Figure 14 shows effects of SARS ([Seq id 285] AEVQIDRLITGRLQSLQTYVCGGEKEKEK) or Filo ISD ([Seq id 286] GAAIGLAWIPYFGPAAECGGEKEKEK) on expression of TNF-alpha mRNA in LPS-stimulated THP-1 cells.
- THP-1 cells were incubated with either medium alone, 30 ⁇ , 60 ⁇ SARS or Filo ISD peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS. Data shown are the medians ⁇ standard deviation from two independent biological replications.
- FIG. 15 shows effects of SARS or Filo ISD on expression of IL-1 ⁇ mRNA in LPS-stimulated THP-1 cells.
- THP-1 cells were incubated with either medium alone, 30 ⁇ , 60 ⁇ SARS or Filo ISD peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS. Data shown are the medians ⁇ standard deviation from two independent biological replications.
- FIG. 16 shows effects of SARS or Filo ISD on expression of IL-1 ⁇ mRNA in LPS-stimulated THP-1 cells.
- THP-1 cells were incubated with either medium alone, 30 ⁇ , 60 ⁇ SARS or Filo ISD peptide or 30 ⁇ , 60 ⁇ control peptide, and stimulated with ⁇ g/ml LPS. Data shown are the medians ⁇ standard deviation from two independent biological replications.
- Figure 17 shows interactions between INF-F#2 peptide and STING depends on distinct STING domains.
- STING was either in a wt form or with deletions. Lysates from tansfected cells were used for pulldown using biotinylated INF-F#2 peptide and streptavidin coated beads. The bead eluate was then immunoblotted using antibodies against HA-tag.
- FIG. 18 Bonemarrow derived dendritic cells (BM DCs) were pretreated with indicated peptides at 5 ⁇ . After 30min cells were then treated with cationic liposomes (Lipo) or iwht lmw(low molecular weight) ds NA (Poly l:C). After 18 hours supernatants were analyzed for type I IFN using a bioassay based on vesicular stomatitis virus (VSV) and L929 cells.
- VSV vesicular stomatitis virus
- INF wt is the INF-F#2 peptide.
- INF D4-6 and INF DI6 are deletion mutants of the INF ISD (negative controls) INF mono is the monomeric form of the peptide that does not have any effect.
- the data show that the INF-F#2 peptide inhibits interferon production induced by liposom fusion with the cells.
- Figure 19 a+b) BMDCs were pretreated with indicated peptides at 5 ⁇ . After 30min cells were then treated with dsDNA ⁇ g/mL) by transfection using lipofectamine 2000. After 18hours supernatants were analyzed for type I IFN using a bioassay based on vesicular stomatitis virus (VSV) and L929 cells, c-e) Human monocyte derived macrophages were treated with virus like particles (Vlp) or cationic liposomes. Cells were either not pretreated or pretreated with INF-F#2 peptide (pFlu). After 4 hours cells were fixed, stained for STING (green) and with DAPI (blue).
- VSV vesicular stomatitis virus
- Vlp virus like particles
- pFlu cationic liposomes
- Influenza peptide or pFlu are identical to INF ISD peptide which is identical to INF-F#2 peptide.
- Figure 20 BMDCs were treated with Iipofectamine2000 according to manufactures directions for usage of Iipofectamine2000 for transfection with DNA (but in this instance without DNA). After 18 hours supernatants were harvested and analyzed for type I IFN by bioassay. Before Iipofectamin2000 treatment cells received either no pretreatment or pretreatment for 30 minutes with INF-F#2 peptide (product). The data shows that the INF-F#2 peptide prevents production of IFN caused by lipofectamine transfection.
- INF-F#2 a peptide from Influenza HA2, blocks type I IFN production induced by membrane fusion.
- transfection reagents such as Lipofectamine2000 from Invitrogen
- Lipofectamine2000 is based on cationic liposomes and function because such liposomes can transport charged molecules such as DNA into living cells.
- the reagent itself is harmful to the treated cells and induce these to produce cytokines such as type I IFN.
- INF-F#2 could also inhibit the response to Lipofectamine2000 we pretreated BMDCs with INF-F#2 for 30min and then treated the cells with Lipofectamine2000 according to instructions by Invitrogen. As seen in Figure 2, INF-F#2 completely blocked the type I IFN response to Lipofectamine.
- INF-F#2 blocks STING signalling in response to cationic liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201370200 | 2013-04-10 | ||
DKPA201370201 | 2013-04-10 | ||
DKPA201370202 | 2013-04-10 | ||
DKPA201370204 | 2013-04-11 | ||
DKPA201370203 | 2013-04-11 | ||
PCT/DK2014/050089 WO2014166500A2 (en) | 2013-04-10 | 2014-04-10 | Peptides having immune suppresive domains for transfection |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2984171A2 true EP2984171A2 (en) | 2016-02-17 |
Family
ID=50685717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14722536.1A Withdrawn EP2984171A2 (en) | 2013-04-10 | 2014-04-10 | Peptides having immune suppresive domains for transfection |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2984171A2 (en) |
WO (1) | WO2014166500A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022529943A (en) | 2019-04-15 | 2022-06-27 | クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー | A fusion protein composition comprising a targeted directed masked type I interferon (IFNA and IFNB) and an antibody against a tumor antigen for use in the treatment of cancer. |
BR112022008865A2 (en) * | 2019-11-07 | 2022-09-20 | Inst Microbiology Cas | VACCINE AGAINST ZIKA/DENGUE AND APPLICATIONS THEREOF. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
FR2860004A1 (en) * | 2003-09-18 | 2005-03-25 | Roussy Inst Gustave | Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus |
EP2212425A2 (en) * | 2007-11-22 | 2010-08-04 | Biontex Laboratories Gmbh | Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system |
TW200932274A (en) | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
-
2014
- 2014-04-10 EP EP14722536.1A patent/EP2984171A2/en not_active Withdrawn
- 2014-04-10 WO PCT/DK2014/050089 patent/WO2014166500A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014166500A3 (en) | 2014-12-24 |
WO2014166500A2 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240033227A1 (en) | Compositions for facilitating membrane fusion and uses thereof | |
JP7078812B2 (en) | Methods for reducing the immunogenicity of RNA | |
ES2633470T3 (en) | Methods and compositions of generating an immune response by inducing CD40 and pattern recognition receptor adapters | |
CN113286603A (en) | Engineered extracellular vesicles and uses thereof | |
ES2623147T3 (en) | Inductive polypeptide sequences of protein bodies | |
NZ740946A (en) | 3’ utr sequences for stabilization of rna | |
WO2006101201A1 (en) | Liposome capable of effective delivery of given substance into nucleus | |
Chang et al. | Cellular delivery of noncovalently-associated macromolecules by cell-penetrating peptides | |
WO2023094713A2 (en) | Coronavirus vaccine | |
AU2022336160A1 (en) | Potency assay for therapeutic potential of coding nucleic acid | |
EP2984171A2 (en) | Peptides having immune suppresive domains for transfection | |
WO2023147092A2 (en) | Coronavirus vaccine | |
WO2022223617A1 (en) | Virus vaccine | |
WO2019103151A1 (en) | Lipid membrane structure for delivering nucleic acid to within cell | |
WO2014166501A2 (en) | Use of immune suppressive peptides as adjuvants | |
CA3237434A1 (en) | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection | |
JP2024514364A (en) | RNA compositions containing buffer substances and methods for their production, storage and use | |
JP7419168B2 (en) | Modified piggyBac transposase polypeptide, polynucleotide encoding it, introduction carrier, kit, method for integrating a target sequence into the genome of a cell, and cell production method | |
WO2023057935A1 (en) | Lipid nanoparticle comprising a nucleic acid-binding protein | |
KR102515464B1 (en) | Cytotoxic mitigating membrane permeable peptides for improving nucleic acid or genetransfection efficiency and use thereof | |
US20240042011A1 (en) | Coronavirus vaccine | |
WO2024026257A2 (en) | Engineered polynucleotides for cell selective expression | |
WO2024038407A1 (en) | Lipid nanoparticle comprising a dna-binding protein | |
WO2024153324A1 (en) | Rna formulations for pharmaceutical use | |
WO2024180054A1 (en) | Linker sequence potency assays for multiple coding nucleic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20151105 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RIIS PALUDAN, SOEREN Inventor name: KANSTRUP HOLM, CHRISTIAN Inventor name: BAHRAMI, SHERVIN |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RIIS PALUDAN, SOEREN Inventor name: KANSTRUP HOLM, CHRISTIAN Inventor name: BAHRAMI, SHERVIN |
|
DAX | Request for extension of the european patent (deleted) | ||
PUAG | Search results despatched under rule 164(2) epc together with communication from examining division |
Free format text: ORIGINAL CODE: 0009017 |
|
17Q | First examination report despatched |
Effective date: 20170217 |
|
B565 | Issuance of search results under rule 164(2) epc |
Effective date: 20170217 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170829 |